 | | Vol. 9.35 – 10 September, 2020 |
| |
|
|
| Scientists developed organoid systems from primary mouse and human induced pluripotent stem cell-derived lung epithelial cells to model early-stage lung adenocarcinoma.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers examined host response gene expression across infection status, viral load, age, and sex among shotgun RNA sequencing profiles of nasopharyngeal swabs from 430 individuals with PCR-confirmed SARS-CoV-2 and 54 negative controls.
[PLoS Biology] |
|
|
|
| The authors demonstrated that MUC4 was overexpressed in idiopathic pulmonary fibrosis patients compared with healthy subjects and located in pulmonary arteries, bronchial epithelial cells, fibroblasts, and hyperplastic alveolar type II cells.
[Mucosal Immunology] |
|
|
|
| Scientists found that hyperoxia and its derivative, reactive oxygen species, upregulated miR-185-5p, but not miR-185-3p, in alveolar cells.
[Cell Death Discovery] |
|
|
|
| | The authors explored the role of pro-survival genes in cancer cell integrity during clonal evolution in non-small cell lung cancer.
[Nature Communications] |
|
|
|
| To identify potential resistance mechanisms, investigators defined the sensitivity of a panel of KRAS G12C mutant lung cancer cell lines to a KRAS G12C inhibitor, AMG510.
[Clinical Cancer Research] |
|
|
|
| Researchers report a novel function of hMENA/hMENAΔv6 isoforms in tumor‐promoting cancer‐associated fibroblasts (CAFs) and in the modulation of pro‐tumoral cancer cell/CAF crosstalk via GAS6/AXL axis regulation.
[EMBO Reports] |
|
|
|
| Scientists showed that genetical or pharmacological blockade of UBE2O impaired tumor progression and radioresistance in lung cancer in vitro and in vivo, and these effects could be restored by Mxi1 inhibition.
[Cell Death & Differentiation] |
|
|
|
| HtrA1, a cisplatin resistance-related gene, was synergistically regulated by HDAC and RXR in NSCLC. Targeting the HDAC/RXR/HtrA1 signaling axis could rescue HtrA1 expression and reverse cisplatin resistance in NSCLC.
[Molecular Cancer] |
|
|
|
|
| Scientists discuss the recently identified subpopulations of alveolar type II cells and their functions under steady state, after injury and in pathological conditions.
[American Journal of Physiology-Cell Physiology] |
|
|
|
|
| Roche announced that the FDA has approved Gavreto™ for the treatment of adults with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by an FDA approved test.
[F. Hoffmann-La Roche Ltd] |
|
|
|
| Savara, Inc. announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase IIa exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial lung infection in people living with cystic fibrosis.
[Savara, Inc.] |
|
|
|
|
|
|
|
| | The University of Southern California – Los Angeles, California, United States |
|
|
|
| | Justus-Liebig-Universität Gießen – Gießen, Germany |
|
|
|
| | NYU Langone Health – New York, New York, United States |
|
|
|
| | Institut Mondor de Recherche Biomédicale (IMRB) – Creteil, France |
|
|
|
| | National Heart and Lung Institute – London, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
